SMAD3 and myeloproliferative neoplasm: Since JAK1/2, SMAD3, or NFκB inhibition prevented the development of the BM-MSC fibrotic phenotype, we wanted to test whether it could reduce or resolve the fibrosis induced by MPN BM-MSCs.